Clinical effect of docetaxel combined with lobaplatin in the treatment of metastatic breast cancer
10.3760/cma.j.issn.1008-6706.2018.07.017
- VernacularTitle:多西他赛联合洛铂治疗转移性乳腺癌的临床效果分析
- Author:
Lixian YANG
1
Author Information
1. 邢台市人民医院乳腺外科
- Keywords:
Metastatic breast cancer;
Docetaxel Breast neoplasms
- From:
Chinese Journal of Primary Medicine and Pharmacy
2018;25(7):878-880
- CountryChina
- Language:Chinese
-
Abstract:
Objective To analyze the efficacy and safety of combination of docetaxel and lobaplatin in the treatment of metastatic breast cancer (MBC).Methods The clinical data of 46 patients with MBC who had been administered docetaxel and lobaplatin were retrospectively reviewed.Results All 46 patients were treated for 4 cycles,4 cases achieved complete remission (CR),25 cases achieved partial remission (PR),the effective rate was 63.0％ (29/46).The patients were followed up for 12 monthpatients,the progression-free survival time was (8.1 ±0.6) months,2 patients died due to tumor progression.The adverse reactions were mainly granulocyte,thrombocytopenia,anemic,gastrointestinal reaction,articular muscle soreness,mucosa,diarrhea and peripheral edema,mainly Ⅰ ～ Ⅱ degree.Conclusion Docetaxel combined with lobaplatin is well-tolerated and safe for MBC patients,and has less adverse reactions.
